Profile of systemic antifungal use in an Intensive Care Unit of a high complexity hospital
DOI:
https://doi.org/10.33448/rsd-v11i6.28385Keywords:
Antifungal Agent; Echinocandins; Health teaching; Intensive care unit.Abstract
In recent decades, there has been a considerable increase in the incidence and diversity of fungal infection. As a result, 1.5 million patients die annually in hospitals due to invasive fungal infections. This article aims to evaluate the profile of antifungal use in adults in the ICU of a University Hospital. This is a cross-sectional and retrospective study carried out in the ICU of the Getúlio Vargas University Hospital, located in the State of Amazonas, belonging to the Unified Health System (SUS), from March/2019 to May/2021. A total of 100 patients were included in the study, the mean age was 53.86 ± 16.11 years, and the mean length of stay in the hospital was 41.08 ± 29.09 days. The main indication for antifungal therapy was the treatment of candida infection, followed by respiratory tract infections. Among the antifungal treatments prescribed, micafungin stood out. When analyzing consumption by DDD, it was observed that there had been a gradual increase in the use of micafungin in recent years. That way, it is concluded that the complications resulting from the infection by COVID-19 changed the profile of use of this important class. In this context, the CCIH is one of pillars for establishing adequate criteria in the choice of antifungal therapy.
References
Agência Nacional de Vigilância Sanitária (ANVISA) (2017). Gerência Geral de Tecnologia em Serviços de Saúde. Gerência de Vigilância e Monitoramento em Serviços de Saúde. Diretriz Nacional para Elaboração de Programa de Gerenciamento do Uso de Antimicrobianos em Serviços de Saúde.
Almeida Silva, F. A. A., Trajano, L. P. B., Nogueira, N. C., Sousa, K. S., Coêlho, M. L. & Nunes, M. R. C. M. J. (2018). Análise do consumo e custo de antifúngicos em um Hospital Universitário, Ciênc. Saúde, 1(1), 61-8.
Bishburg, E., Okoh, A., Nagarakanti, S.R., Lindner, M., Migliore, C. & Patel, P. (2021). Fungemia in COVID‐19 ICU patients, a single medical center experience. J Med Virol, 93, 2810–2814.
Boonstra, J. M., van der Elst, K. C., Veringa, A., Jongedijk, E. M., Brüggemann, R. J., Koster, R. A., Kampinga, G. A., Kosterink, J. G., van der Werf, T. S., Zijlstra, J. G., Touw, D. J., & Alffenaar, J. W. C. (2017). Pharmacokinetic properties of micafungin in critically ill patients diagnosed with invasive candidiasis. Antimicrobial Agents and Chemotherapy, 61(12), e01398-17. https://doi.org/10.1128/AAC.01398-17.
Collado, R., Losa, J. E., Álvaro, E. A., Toro, P., Moreno, L. & Pérez, M. (2015). Evaluación del consumo de antimicrobianos mediante DDD/100 estancias versus DDD/100 altas em la implantación de un Programa de Optimización del Uso de Antimicrobianos. Rev Esp Quimioter, 28(6), 317-321.
Colombo, A. L., Nucci, M., Park, B. J., Nouér, S. A., Arthington-Skaggs, B., da Matta, D. A., Warnock, D., Morgan, J., & Brazilian Network Candidemia Study (2006). Epidemiology of candidemia in Brazil: a nationwide sentinel surveillance of candidemia in eleven medical centers. Journal of clinical microbiology, 44(8), 2816–2823. https://doi.org/10.1128/JCM.00773-06.
Cortes, L. J. A. & Russi, N. J. A. (2011). Equinocandinas. Rev Chil Infect., 28(6), 529-536.
Gomes, M. J. V. M. & Reis, A. M. M. (2001). Ciências farmacêuticas: uma abordagem em farmácia hospitalar. 1sd. São Paulo, Atheneu, 559.
Herbrecht, R., Nivoix, Y., Fohrer, C., Natarajan-Amé, S. & Letscher-Bru, V. (2005). Management of systemic fungal infections: alternatives to itraconazole. J Antimicrob Chemother, 56(1), 39-48.
Kim, E. J., Lee, E., Kwak, Y. G., Yoo, H. M., Choi, J. Y., Kim, S. R., Shin, M. J., Yoo, S., Cho, N., & Choi, Y. H. (2020). Trends in the Epidemiology of Candidemia in Intensive Care Units From 2006 to 2017: Results From the Korean National Healthcare-Associated Infections Surveillance System. Frontiers in Medicine, 7, 606976.
Koehler, P., Stecher, M., Cornely, O. A., Koehler, D., Vehreschild, M., Bohlius, J., Wisplinghoff, H., & Vehreschild, J. J. (2019). Morbidity and mortality of candidaemia in Europe: an epidemiologic meta-analysis. Clinical microbiology and infection: the official publication of the European Society of Clinical Microbiology and Infectious Diseases, 25(10), 1200–1212. https://doi.org/10.1016/j.cmi.2019.04.024.
Kovács, R., Tóth, Z., Locke, J. B., Forgács, L., Kardos, G., Nagy, F., Borman, A. M., & Majoros, L. (2021). Comparison of In Vitro Killing Activity of Rezafungin, Anidulafungin, Caspofungin, and Micafungin against Four Candida auris Clades in RPMI-1640 in the Absence and Presence of Human Serum. Microorganisms, 9(4), 863. https://doi.org/10.3390/microorganisms9040863.
Lin, S.J., Schranz, J. & Teutsch, S. M. (2001). Aspergillosis case-fatality rate: systematic review of the literature. Clinical Infectious Diseases, 32(3), 358-66.
Lumbreras, C., Lizasoain, M. & Aguado, J.M. (2003). Antifúngicos de uso sistémico. Enfermedades Infecciosas y Microbiología Clínica, 21(7), 366-380.
Macauley, P. & Epelbaum, O. (2021). Epidemiology and Mycology of Candidaemia in non‐oncological medical intensive care unit patients in a tertiary center in the United States: Overall analysis and comparison between non‐COVID‐19 and COVID‐19 cases. Mycoses, 64(6), 634–640.
Mondain, V., Lieutier, F., Hasseine, L., Gari-Toussaint, M., Poiree, M., Lions, C., & Pulcini, C. (2013). A 6-year antifungal stewardship programme in a teaching hospital. Infection, 41(3), 621–628. https://doi.org/10.1007/s15010-013-0431-1.
Nucci, M., Barreiros, G., Guimarães, L. F., Deriquehem, V. A. S., Castiñeiras, A. C. & Nouér, S. A. (2021). Increased incidence of candidemia in a tertiary care hospital with the COVID-19 pandemic. Mycoses, 64(2), 152-156.
Onzi, P. S., Hoffman, S. P. & Camargo, A. L. (2011). Avaliação do consumo de antimicrobianos injetáveis de um hospital privado no ano de 2009. Rev. Bras. Farm. Hosp. Serv. Saúde, 2(2), 20-5.
Prentice, H. G., Kibbler, C. C. & Prentice, A. G. (2000). Towards a targeted, risk-based, antifungal strategy in neutropenic patients. British Journal of Haematology, 110(2), 273-284.
Rodrigues, F. D. & Bertoldi, A. D. (2010). Perfil de utilização de antimicorbianos de um hospital privado. Ciênc. Saúde Colet, 15(Supl. 1), 1239-1247.
Sardi, J. C. O., Pitangui, N. S., Gullo, F. P., Almeida, A. M. F. & Giannini, M. J. S. M. (2013). A Mini Review of Candida Species in Hospital Infection: Epidemiology, Virulence Factor and Drugs Resistance and Prophylaxis. Trop Med Surg, 1.
Sosa-García, J. O., Gutiérrez-Villaseñor, A. O., García-Briones, A., Romero-González, J. P., Juárez-Hernández, E. & González-Chon, O. (2020). Experience in the management of severe COVID-19 patients in an intensive care unit. Experiencia en el manejo de pacientes graves con COVID-19 en una unidad de terapia intensiva. Cir Cir, 88(5), 569-575.
Souza, F. C., Baroni, M. M. F. & Roese, F. M. (2017). Perfil de utilização de antimicrobianos na unidade de terapia intensiva de um hospital público. Rev. Bras. Farm. Hosp. Serv. Saúde, 8(4), 37-44.
Wasmann, R. E., Muilwijk, E. W., Burger, D. M., Verweij, P. E., Knibbe, C.A. & Brüggemann, R. J. (2018). Clinical Pharmacokinetics and Pharmacodynamics of Micafungin. Clin Pharmacokinet, 57(3), 267-286.
Zarb, P., Amadeo, B., Muller, A., Drapier, N., Vankerckhoven, V., Davey, P. & Goossens, H. (2012). Antifungal therapy in European hospitals: data from the ESAC point-prevalence surveys 2008 and 2009. Clin Microbiol Infect, 18, E389–E395.
Zuo, X-S., Liu, Y. & Hu, K. (2021). Epidemiology and risk factors of candidemia due to Candida parapsilosis in an intensive care unit. Rev Inst Med Trop São Paulo, 63(20).
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Sabrina Santarém de Moraes; Rebeka Caribé Badin
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
